KR101355830B1 - Pharmaceutical compositions and functional food for diabetes prevention comprising allyl isocyanate - Google Patents
Pharmaceutical compositions and functional food for diabetes prevention comprising allyl isocyanate Download PDFInfo
- Publication number
- KR101355830B1 KR101355830B1 KR1020120112964A KR20120112964A KR101355830B1 KR 101355830 B1 KR101355830 B1 KR 101355830B1 KR 1020120112964 A KR1020120112964 A KR 1020120112964A KR 20120112964 A KR20120112964 A KR 20120112964A KR 101355830 B1 KR101355830 B1 KR 101355830B1
- Authority
- KR
- South Korea
- Prior art keywords
- allyl isocyanate
- preventing
- pharmaceutical composition
- diabetes
- functional food
- Prior art date
Links
- HXBPYFMVGFDZFT-UHFFFAOYSA-N allyl isocyanate Chemical compound C=CCN=C=O HXBPYFMVGFDZFT-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- 235000013376 functional food Nutrition 0.000 title claims abstract description 18
- 230000002265 prevention Effects 0.000 title description 2
- 210000004369 blood Anatomy 0.000 claims abstract description 40
- 239000008280 blood Substances 0.000 claims abstract description 40
- 230000036541 health Effects 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 235000000346 sugar Nutrition 0.000 claims abstract description 11
- 241000219198 Brassica Species 0.000 claims description 13
- 239000006188 syrup Substances 0.000 claims description 7
- 235000020357 syrup Nutrition 0.000 claims description 7
- 240000007124 Brassica oleracea Species 0.000 claims description 6
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 6
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 6
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- -1 flakes Substances 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 235000003351 Brassica cretica Nutrition 0.000 claims description 3
- 240000002791 Brassica napus Species 0.000 claims description 3
- 235000011293 Brassica napus Nutrition 0.000 claims description 3
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 3
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 3
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 3
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 claims description 3
- 235000003343 Brassica rupestris Nutrition 0.000 claims description 3
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 235000015110 jellies Nutrition 0.000 claims description 3
- 235000010460 mustard Nutrition 0.000 claims description 3
- 235000021028 berry Nutrition 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 46
- 239000008103 glucose Substances 0.000 abstract description 45
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 11
- 241000219193 Brassicaceae Species 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 25
- 235000005911 diet Nutrition 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 230000037213 diet Effects 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 13
- 238000009472 formulation Methods 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 108091005995 glycated hemoglobin Proteins 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000008213 purified water Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000007446 glucose tolerance test Methods 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008227 sterile water for injection Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 101150046735 LEPR gene Proteins 0.000 description 2
- 101150063827 LEPROT gene Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PHZOWSSBXJXFOR-MYMDCHNCSA-N Sinigrin Natural products S(=O)(=O)(O/N=C(\S[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)/CC=C)O PHZOWSSBXJXFOR-MYMDCHNCSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PHZOWSSBXJXFOR-UHFFFAOYSA-N 2-Propenyl glucosinolate Natural products OCC1OC(SC(CC=C)=NOS(O)(=O)=O)C(O)C(O)C1O PHZOWSSBXJXFOR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- QKFAFSGJTMHRRY-OCFLFPRFSA-M potassium;[(e)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanylbut-3-enylideneamino] sulfate Chemical compound [K+].OC[C@H]1O[C@@H](S\C(CC=C)=N\OS([O-])(=O)=O)[C@H](O)[C@@H](O)[C@@H]1O QKFAFSGJTMHRRY-OCFLFPRFSA-M 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003044 randomized block design Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- PHZOWSSBXJXFOR-PTGZALFTSA-N sinigrin Chemical compound OC[C@H]1O[C@@H](S\C(CC=C)=N\OS(O)(=O)=O)[C@H](O)[C@@H](O)[C@@H]1O PHZOWSSBXJXFOR-PTGZALFTSA-N 0.000 description 1
- 235000017291 sinigrin Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/045—Organic compounds containing nitrogen as heteroatom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 체내 글루코오스 및 혈중 혈당을 감소시키고 인슐린의 민감도를 증가시킬 수 있는 알릴이소시아네이트를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물 및 건강기능식품에 관한 것이다. The present invention relates to a pharmaceutical composition and health functional food for preventing or treating diabetes containing allyl isocyanate as an active ingredient which can reduce glucose and blood glucose in the body and increase the sensitivity of insulin.
당뇨병은 혈액 내에 존재하는 포도당이 소변을 통해 배출되는 질환으로서, 근본적인 치유가 되지 않는 만성퇴행성 질환 중의 하나이다. 현대에 들어와서 식생활의 변화와 운동 부족 등으로 인하여 인체 고유의 에너지 대사과정에 커다란 변화가 발생하였으며, 이에 따라 당뇨병 등의 만성퇴행성 질환이 증가하는 현상을 보이고 있다.Diabetes is a disease in which glucose in the blood is excreted through urine and is one of the chronic degenerative diseases that is not fundamentally cured. In modern times, due to changes in diet and lack of exercise, a great change occurred in the body's own energy metabolism process, resulting in an increase in chronic degenerative diseases such as diabetes.
국내에서는 당뇨 유병율이 5 내지 10%에 달하는 것으로 알려져 있으며 지속적인 증가를 보이고 있다. 미국의 경우에는 지난 40년간 당뇨병이 6배 증가하였으며, 이와 같은 수준의 증가율에 따르면 2050년에는 환자수가 2600만명에 이르게 될 것으로 전망하고 있다.Diabetes prevalence is known to reach 5 to 10% in Korea and is showing a continuous increase. In the United States, diabetes has increased six-fold over the last 40 years, and this growth rate is projected to reach 26 million in 2050.
당뇨병은 인슐린 작용, 인슐린 분비 또는 이들 두 가지 모두의 결함으로 발생되는 고혈당을 특징으로 하는 대사장애증후군이다. 당뇨병을 일으키는 원인으로는 자가면역기전에 의한 인슐린 저항성 등 다양하며, 대부분의 환자들의 경우 인슐린 분비 장애 및 인슐린 저항성 등이 동시에 존재하는 경우가 많다. 이러한 당뇨병은 고혈당이 만성으로 지속되면서 당질 대사뿐만 아니라 지질 및 단백질의 대사에도 장애를 일으켜, 망막, 신장, 신경, 심혈관계 등의 합병증을 유발시킨다. Diabetes is a metabolic syndrome characterized by hyperglycemia caused by a deficiency in insulin action, insulin secretion, or both. The causes of diabetes are various, such as insulin resistance due to autoimmune mechanism, and in most patients, insulin secretion disorder and insulin resistance are often present at the same time. This diabetes causes chronic hyperglycemia and causes disorders in lipid and protein metabolism as well as carbohydrate metabolism, leading to complications such as retina, kidney, nerve, and cardiovascular system.
당뇨병은 산화적 스트레스가 인슐린 저항성, 제1형 및 제2형 당뇨의 원인으로 간주 되고 있다(Ceriello et al. Metabolism 2000;49:27). 고혈당은 체내에서 산화적 스트레스를 발생시키며, 이로 인하여 수퍼옥사이드 이온, 단백질의 당질화, 그리고 포도당의 자동산화가 일어나게 된다(Brownlee. Nature 2001;414:813, Baynes. Clin Chem Lab Med 2003;41:813, Wollff et al. Biochem J 1987;245:243, Wolff Free Radic Biol Med 1991;10:339).In diabetes, oxidative stress is considered to be the cause of insulin resistance,
제2형 당뇨 및 그 합병증은 장기적으로 일상생활의 식이 및 생활습관을 통하여 자연스럽게 치료해 나가야 하므로, 독성을 갖는 의약품은 한계가 있어 식품의 형태로 장기적으로 섭취할 수 있는 부작용이 없는 안전한 당뇨 예방 및 치료제의 개발이 시급한 실정이다.
이에 따라, 독성을 갖지 않는 재료를 이용한 당뇨병 예방 및 치료제가 요구되고 있다.Accordingly, there is a need for a preventive and therapeutic agent for diabetes using a material that is not toxic.
본 발명의 목적은 체내 글루코오스 및 혈중 혈당을 감소시키고 인슐린의 민감도를 증가시킬 수 있는 알릴이소시아네이트를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물을 제공하는데 있다.An object of the present invention to provide a pharmaceutical composition for preventing or treating diabetes containing allyl isocyanate as an active ingredient capable of reducing glucose and blood glucose in the body and increasing the sensitivity of insulin.
또한 본 발명의 다른 목적은 알릴이소시아네이트를 유효성분으로 함유하는 건강기능식품을 제공하는데 있다.In addition, another object of the present invention to provide a health functional food containing allyl isocyanate as an active ingredient.
상기한 목적을 달성하기 위한 본 발명의 당뇨병 예방 또는 치료용 약학 조성물은 알릴이소시아네이트(allyl isocyanate)를 유효성분으로 함유할 수 있다.The pharmaceutical composition for preventing or treating diabetes of the present invention for achieving the above object may contain allyl isocyanate as an active ingredient.
상기 알릴이소시아네이트는 겨자과 식물로부터 유래된 것일 수 있으며, 겨자과 식물은 배추, 양배추, 순무, 브로콜리 또는 겨자일 수 있다.The allyl isocyanate may be derived from a mustard plant, and the mustard plant may be cabbage, cabbage, turnip, broccoli or mustard.
상기 알릴이소시아네이트는 겨자과 식물의 잎사귀, 열매 또는 종자로부터 얻어진 것일 수 있다.The allyl isocyanate may be obtained from leaves, fruits or seeds of the mustard plant.
상기 알릴이소시아네트의 함량은 총 약학 조성물을 기준으로 0.001 내지 15 중량%일 수 있다.The content of the allyl isocyanate may be 0.001 to 15% by weight based on the total pharmaceutical composition.
상기한 다른 목적을 달성하기 위한 본 발명의 당뇨병 예방 또는 개선용 건강기능식품은 알릴이소시아네이트(allyl isocyanate)를 유효성분으로 함유할 수 있다.Health functional foods for preventing or improving diabetes of the present invention for achieving the above another object may contain allyl isocyanate as an active ingredient.
상기 건강기능식품은 혈당강하용일 수 있으며, 캡슐, 정제, 분말, 과립, 액상, 환, 편상, 페이스트상, 시럽, 겔, 젤리 및 바로 이루어진 군에서 선택될 수 있다.The health functional food may be for lowering blood sugar, and may be selected from the group consisting of capsules, tablets, powders, granules, liquids, pills, flakes, pastes, syrups, gels, jellies, and bars.
본 발명의 알릴이소시아네이트를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물은 체내 글루코오스 및 혈중 혈당을 감소시키고 인슐린의 민감도를 증가시키므로 당뇨 예방 및 치료효과가 매우 우수하다.The pharmaceutical composition for preventing or treating diabetes containing allyl isocyanate of the present invention as an active ingredient is excellent in preventing and treating diabetes because it reduces glucose and blood glucose in the body and increases the sensitivity of insulin.
또한, 본 발명의 당뇨병 예방 또는 치료용 약학 조성물은 독성이 없으므로 식품의 형태로 섭취할 수 있어 장기적으로 일상생활의 식이 및 생활습관을 통하여 당뇨 및 당뇨 합병증을 예방할 수 있을 뿐만 아니라 당뇨 치료제로서 유용하게 상용될 수 있다.In addition, since the pharmaceutical composition for preventing or treating diabetes of the present invention is not toxic, it can be ingested in the form of food, which can prevent diabetes and diabetic complications through diet and lifestyle of daily life in the long term, and is useful as a diabetic treatment agent. It may be commercially available.
또한, 본 발명의 건강기능식품은 당뇨병을 예방 또는 개선할 수 있다.In addition, the health functional food of the present invention can prevent or improve diabetes.
도 1은 AIN-76 실험식이군 및 AIN-76 실험식이 급여와 동시에 알릴이소시아네이트를 경구 투여한 군에 대한 주별 공복 혈당 수치를 나타낸 그래프이다.
도 2는 AIN-76 실험식이군 및 AIN-76 실험식이 급여와 동시에 알릴이소시아네이트를 경구 투여한 군을 IP ITT 방법으로 처리한 후 시간별 혈당 수치 변화를 나타낸 그래프이다.
도 3은 AIN-76 실험식이군 및 AIN-76 실험식이 급여와 동시에 알릴이소시아네이트를 경구 투여한 군을 IP ITT 방법으로 처리하여 혈당의 누적 농도를 나타낸 그래프이다.
도 4는 AIN-76 실험식이군 및 AIN-76 실험식이 급여와 동시에 알릴이소시아네이트를 경구 투여한 군을 IP GTT 방법으로 처리하여 글루코스 투여 후 시간별 혈당의 변화를 나타낸 그래프이다.
도 5는 AIN-76 실험식이군 및 AIN-76 실험식이 급여와 동시에 알릴이소시아네이트를 경구 투여한 군을 IP GTT 방법으로 처리하여 혈당의 누적 농도를 나타낸 그래프이다.
도 6은 AIN-76 실험식이 급여와 동시에 알릴이소시아네이트를 경구 투여한 군의 당화혈색소 측정결과를 나타낸 그래프이다.
도 7은 알릴이소시아네이트(AIC) 및 알릴이소사이오시아네이트(AITC)로 처리된 NIT-1 췌장세포의 생존율을 나타낸 그래프이다. FIG. 1 is a graph showing weekly fasting blood glucose levels for the AIN-76 experimental diet group and the AIN-76 experimental diet group and orally administered allyl isocyanate.
Figure 2 is a graph showing changes in blood glucose levels over time after treatment with the AIN-76 dietary group and the AIN-76 experimental diet and the group orally administered allyl isocyanate at the same time as the IP ITT method.
Figure 3 is a graph showing the cumulative concentration of blood sugar by treatment with the AIT-76 experimental diet group and the AIN-76 experimental diet and the group orally administered allyl isocyanate at the same time as the IP ITT method.
4 is a graph showing changes in blood glucose over time after glucose administration by treatment with the AIN-76 dietary group and the AIN-76 experimental diet with the group administered orally with allyl isocyanate at the same time as the IP GTT method.
FIG. 5 is a graph showing the cumulative concentration of blood glucose by treatment with the AIN-76 dietary group and the AIN-76 experimental diet with the group administered orally with allyl isocyanate by the IP GTT method.
Figure 6 is a graph showing the results of measurement of glycated hemoglobin in the group orally administered allyl isocyanate at the same time as the AIN-76 diet.
Figure 7 is a graph showing the survival rate of NIT-1 pancreatic cells treated with allyl isocyanate (AIC) and allyl isocyanocyanate (AITC).
본 발명은 체내 글루코오스 및 혈중 혈당을 감소시키고 인슐린의 민감도를 증가시킬 수 있는 알릴이소시아네이트를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물 및 건강기능식품에 관한 것이다.
The present invention relates to a pharmaceutical composition and health functional food for preventing or treating diabetes containing allyl isocyanate as an active ingredient which can reduce glucose and blood glucose in the body and increase the sensitivity of insulin.
이하, 본 발명을 상세하게 설명한다. Hereinafter, the present invention will be described in detail.
본 발명의 당뇨병 예방 또는 치료용 약학 조성물 및 건강기능식품은 알릴이소시아네이트(allyl isocyanate)를 유효성분으로 포함하며, 상기 알릴이소시아네이트는 겨자과 식물로부터 유래된다.The pharmaceutical composition and health functional food for preventing or treating diabetes of the present invention include allyl isocyanate as an active ingredient, and the allyl isocyanate is derived from a mustard plant.
상기 겨자과 식물은 배추, 양배추, 순무, 브로콜리 및 겨자로 이루어진 군에서 선택된 1종이며, 상기 식물의 잎사귀, 열매 또는 종자로부터 알릴이소시아네이트가 얻어진다. 구체적으로, 겨자과 식물에 존재하는 글루코시놀레이트(glucosinolate)인 알릴글루코시놀레이트(allyl glucosinolate), 예컨대 시니그린(sinigrin)이 겨자과 식물의 잎사귀, 열매 또는 종자를 마쇄할 때 그 조직 내에 존재하는 사이오글루코시데이스에 의하여 가수분해되어 알릴이소시아네이트가 형성된다.The mustard plant is one selected from the group consisting of cabbage, cabbage, turnip, broccoli and mustard, and allyl isocyanate is obtained from the leaves, berries or seeds of the plant. Specifically, allyl glucosinolate, a glucosinolate present in mustard plants, such as sinigrin, is present in the tissues when grinding leaves, fruits or seeds of mustard plants. Hydrolysed by Cioglucosidase to form allyl isocyanate.
본 발명의 알릴이소시아네이트를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물은 알릴이소시아네이트를 약학 조성물 총 중량을 기준으로 0.001 내지 15 중량%, 바람직하게는 0.01 내지 12 중량% 포함한다.The pharmaceutical composition for preventing or treating diabetes containing allyl isocyanate of the present invention as an active ingredient comprises allyl isocyanate at 0.001 to 15% by weight, preferably 0.01 to 12% by weight, based on the total weight of the pharmaceutical composition.
상기 당뇨병 예방 또는 치료용 약학 조성물은 다양한 경구 또는 비경구 투여 형태로 제형화될 수 있다. The pharmaceutical composition for preventing or treating diabetes may be formulated in various oral or parenteral dosage forms.
경구 투여용 제형으로는 예를 들면 정제, 환제, 경질, 연질 캅셀제, 액제, 현탁제, 유화제, 시럽제, 과립제 등이 있는데, 이들 제형은 유효성분 이외에 희석제(예: 락토즈, 덱스트로즈, 수크로즈, 만니톨, 솔비톨, 셀룰로즈 및/또는 글리신), 활택제(예: 실리카, 탈크, 스테아르산 및 그의 마그네슘 또는 칼슘염 및/ 또는 폴리에틸렌 글리콜)를 추가로 포함할 수 있다. 또한, 상기 정제는 마그네슘 알루미늄 실리케이트, 전분 페이스트, 젤라틴, 트라가칸스, 메틸셀룰로즈, 나트륨 카복시메틸셀룰로즈 및/또는 폴리비닐피롤리딘과 같은 결합제를 함유할 수 있으며, 경우에 따라 전분, 한천, 알긴산 또는 그의 나트륨 염과 같은 붕해제 또는 비등 혼합물 및/또는 흡수제, 착색제, 향미제 및 감미제를 함유할 수 있다. 상기 제형은 통상적인 혼합, 과립화 또는 코팅 방법에 의해 제조될 수 있다.Formulations for oral administration include, for example, tablets, pills, hard capsules, soft capsules, solutions, suspensions, emulsifiers, syrups, granules, etc. These formulations may contain diluents (e.g., lactose, dextrose, water, etc.) in addition to the active ingredients. Cross, mannitol, sorbitol, cellulose and / or glycine), lubricants such as silica, talc, stearic acid and its magnesium or calcium salts and / or polyethylene glycols. The tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidine, optionally starch, agar, alginic acid. Or disintegrant or boiling mixtures such as sodium salts thereof and / or absorbents, colorants, flavors and sweeteners. The formulations may be prepared by conventional mixing, granulating or coating methods.
또한, 비경구 투여용 제형의 대표적인 것은 주사용 제제이며, 주사용 제제의 용매로서 물, 링거액, 등장성 생리식염수 또는 현탁액을 들 수 있다. 상기 주사용 제제의 멸균 고정 오일은 용매 또는 현탁 매질로서 사용할 수 있으며 모노-, 디-글리세라이드를 포함하여 어떠한 무자극성 고정오일도 이러한 목적으로 사용될 수 있다. 또한, 상기 주사용 제제는 올레산과 같은 지방산을 사용할 수 있다.Representative of parenteral formulations are also injectable preparations, which may include water, Ringer's solution, isotonic saline or suspensions as solvents for injectable preparations. Sterile fixed oils of the injectable preparations may be used as solvents or suspending media and any non-irritating fixed oil may be used for this purpose, including mono- and di-glycerides. In addition, the injectable preparation may use a fatty acid such as oleic acid.
본 발명의 알릴이소시아네이트를 유효성분으로 함유한 당뇨병 예방 또는 치료용 약학 조성물의 투여량은 환자의 연령, 성별, 체중, 질환의 중증도에 따라 달라지나, 본 발명의 약학 조성물은 환자의 무게 1 kg 당 300 mg 이하, 바람직하게는 100 내지 200 mg을 1일 1-4회 투여하나 이에 한정되는 것은 아니다.The dosage of the pharmaceutical composition for preventing or treating diabetes containing allyl isocyanate of the present invention as an active ingredient depends on the age, sex, weight, and severity of the disease of the patient, but the pharmaceutical composition of the present invention is used per 1 kg of the patient's weight. 300 mg or less, preferably 100 to 200 mg is administered 1 to 4 times a day, but is not limited thereto.
상기 본 발명의 알릴이소시아네이트를 유효성분으로 함유하는 당뇨병 예방 또는 개선용 건강기능식품은 혈당강하용으로 사용될 수 있으며, 건강기능식품 총 중량을 기준으로 알릴이소시아네이트를 0.0001 내지 10 중량%로 함유한다. The health functional food for preventing or improving diabetes containing allyl isocyanate of the present invention as an active ingredient can be used for lowering blood sugar, and contains 0.0001 to 10% by weight of allyl isocyanate based on the total weight of the health functional food.
상기 건강기능식품은 일상식사에서 부족할 수 있는 영양소를 보충하거나 인체에 유용한 기능성 원료를 보충할 목적으로 캡슐, 정제, 분말, 과립, 액상, 환, 편상, 페이스트상, 시럽, 겔, 젤리 및 바로 이루어진 군 중에서 선택되어 1회 섭위가 용이하게 제조 및 가동된 것이다.The health functional food is made up of capsules, tablets, powders, granules, liquids, pills, tablets, pastes, syrups, gels, jelly and bars for the purpose of supplementing nutrients that may be lacking in daily meals or supplementing functional ingredients useful to the human body. It is selected from the group and one-time preparation is easily manufactured and operated.
또한, 상기 건강기능식품은 제형에 따라 포도당, 구연산, 액상 올리고당, 옥수수 시럽(corn syrup), 대두 레시틴, 버터, 식물성 경화류, 탈지우유, 설탕, 마가린, 식염, 전분, 밀가루, 물엿, 맥아당, 중조 및 당 에스테르 등의 통상적으로 사용되는 성분들을 이용하여 제조될 수 있다.
In addition, the health functional food is glucose, citric acid, liquid oligosaccharides, corn syrup (corn syrup), soy lecithin, butter, vegetable cured, skim milk, sugar, margarine, salt, starch, flour, syrup, maltose, It may be prepared using commonly used ingredients such as sodium bicarbonate and sugar esters.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시하나, 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범주 및 기술사상 범위 내에서 다양한 변경 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속하는 것도 당연한 것이다.It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the present invention. Such variations and modifications are intended to be within the scope of the appended claims.
마우스 준비Mouse preparation
실험동물은 5주령의 수컷 C57BLKS/J Iar-+Leprdb/ + Leprdb 마우스 20마리를 한국생명공학연구원(대전, 한국)로부터 구입하였다. 실험 시작 전 1주일간 적응시킨 후 난괴법(randomized block design)에 의하여 2개 군의 마우스를 4주간 사육하였다. 본 실험에 사용한 식이는 AIN-76 기본 실험 식이로, 모든 시험물질은 매일 동일한 시간에 경구 투여하였다. Experimental animals were 5 weeks old male C57BLKS / J Iar- + Lepr db / +
-2개 군의 마우스-2 groups of mice
A: AIN-76 실험식이군 10마리(비교예)A: 10 AIN-76 dietary groups (comparative)
B: AIN-76 실험식이 급여와 동시에 알릴이소시아네이트(AIC) 25 mg/kg 경구 투여군 10마리(실시예)
B: 10 allyl isocyanate (AIC) 25 mg / kg oral administration group at the same time as the AIN-76 experimental diet (Example)
시험예Test Example 1. 혈당측정 1. Blood glucose measurement
A 및 B군 마우스들의 식이를 측정 전에 제거하여 4시간 절식시킨 후 공복상태에서 꼬리정맥으로부터 채혈하여 혈당측정기(G-doctor, Greencross, Korea)를 이용하여 공복혈당 수치를 실험식이 급여 후 0, 1, 2, 3 및 4주에 측정하였으며, 그 평균값을 도 1에 나타내었다. The diets of group A and B mice were removed before fasting and fasted for 4 hours, and then collected from the tail vein in a fasted state, and the fasting blood glucose level was measured using a blood glucose meter (G-doctor, Greencross, Korea). , 2, 3 and 4 weeks were measured, the average value is shown in FIG.
도 1에 도시된 바와 같이, 알릴이소시아네이트를 경구 투여한 B군의 마우스는 알릴이소시아네이트를 투여하지 않은 A군의 마우스에 비하여 공복 혈당 상승이 억제되는 것으로 확인되었다. 그러므로 알릴이소시아네이트가 혈당 상승 억제 효과가 있다는 것을 알 수 있다.
As shown in FIG. 1, the group B mice orally administered with allyl isocyanate were found to inhibit fasting blood glucose elevation as compared to the group A mice not administered with allyl isocyanate. Therefore, it can be seen that allyl isocyanate has a blood glucose raising inhibitory effect.
시험예Test Example 2. 2. IPIP ITTITT (( 복강내Abdominal cavity 인슐린 내성검사) Insulin resistance test)
A 및 B군 마우스들의 식이를 측정 전에 제거하여 4시간 절식시킨 후 공복상태에서 꼬리정맥으로부터 채혈하여 혈당측정기(G-doctor, Greencross, Korea)를 이용하여 글루코스 수치를 측정한 후 1.35 unit/kg 농도의 인슐린이 함유된 인슐린 용액(멸균 주사용수 사용, 4 ℃보관)을 마우스의 복강에 투여한 후 혈당측정기로 15, 30, 60, 90, 120분에 글루코스 수치를 측정하였으며, 그 평균값을 도 2 및 3에 나타내었다.The diets of group A and B mice were removed before fasting and fasted for 4 hours, and then collected from the tail vein in a fasted state, and glucose levels were measured using a blood glucose meter (G-doctor, Greencross, Korea). Insulin solution containing sterile insulin (using sterile water for injection, stored at 4 ° C.) was administered to the abdominal cavity of mice, and glucose levels were measured at 15, 30, 60, 90 and 120 minutes using a blood glucose meter. And 3.
도 2 및 도 3에 도시된 바와 같이, 알릴이소시아네이트를 경구 투여한 B군의 마우스는 알릴이소시아네이트를 투여하지 않은 A군의 마우스에 비하여 인슐린에 의한 혈당 감소 효과가 효과적으로 유도되는 것으로 확인되었다. 또한, 혈당 누적 농도(area under curve, AUC) 역시 알릴이소시아네이트를 투여한 B군의 마우스가 A군에 비하여 낮은 것으로 확인되었다.As shown in Figures 2 and 3, it was confirmed that the group B mice orally administered allyl isocyanate effectively induces blood glucose reduction effect by insulin as compared to the group A mice not administered allyl isocyanate. In addition, the blood glucose concentration (area under curve, AUC) was also found to be lower than the group A mice to which allyl isocyanate was administered.
상기 결과를 통하여, 알릴이소시아네이트가 인슐린 민감도를 증가시킨다는 것을 알 수 있다.
The results show that allyl isocyanate increases insulin sensitivity.
인슐린 민감도에 대한 설명은 다음과 같다.Description of insulin sensitivity is as follows.
혈액에 있는 포도당을 에너지원으로 사용하기 위해서는 인슐린이 중요한 역할을 하는데 각 세포막에 있는 인슐린 수용체를 통해 포도당을 각 세포에 공급해준다. 그러나 각 세포들의 인슐린 수용체의 민감도가 떨어지게 되면, 세포가 포도당이 도착한 것을 인지하지 못하여 포도당을 제대로 흡수할 수 없으므로 결국 남은 포도당이 혈액을 떠돌아다니며 혈당을 높이게 된다. Insulin plays an important role in the use of glucose in the blood as an energy source, supplying glucose to each cell through the insulin receptor on each cell membrane. However, when each cell's insulin receptors are less sensitive, the cells do not recognize the arrival of the glucose and cannot absorb it properly, so the remaining glucose floats the blood and raises the blood sugar.
또한 인슐린 민감도가 낮은 상태인 인슐린 저항성이 오랜 기간 지속이 되면, 우리 몸에서 인슐린을 만들어 내는 능력이 한계에 부딪히게 되어 인슐린 분비가 줄어들게 되고, 이렇게 균형이 깨지게 되면 부족한 인슐린 분비로 인해 혈당이 올라가게 되어 인슐린 저항성이 더 높아지게 된다.
In addition, if insulin resistance persists for a long time with low insulin sensitivity, our body's ability to make insulin hits the limit, which reduces insulin secretion. When this balance is broken, blood sugar rises due to insufficient insulin secretion. This leads to higher insulin resistance.
시험예Test Example 3. 3. IPIP GTTGTT (( 복강내Abdominal cavity 글루코스Glucose 내성검사) Tolerance test)
A 및 B군 마우스들의 식이를 측정 전에 제거하여 4시간 절식시킨 후 공복상태에서 꼬리정맥으로부터 채혈하여 혈당측정기(G-doctor, Greencross, Korea)를 이용하여 글루코스 수치를 측정한 후 2g/kg 농도의 글루코스가 함유된 글루코스 용액(멸균 주사용수 사용, 4 ℃보관)을 마우스의 복강에 투여한 후 혈당측정기로 15, 30, 60, 120분에 글루코스 수치를 측정하였으며, 그 평균값을 도 4 및 5에 나타내었다.The diets of group A and B mice were removed before fasting and fasted for 4 hours, and then collected from the tail vein in a fasted state, and glucose levels were measured using a blood glucose meter (G-doctor, Greencross, Korea). Glucose solution containing glucose (using sterile water for injection, stored at 4 ° C.) was administered to the abdominal cavity of mice, and glucose levels were measured at 15, 30, 60, and 120 minutes using a blood glucose meter. Indicated.
도 4 및 도 5에 도시된 바와 같이, 알릴이소시아네이트를 경구 투여한 B군의 마우스는 A군의 마우스에 비하여 글루코스 수치가 30분 까지는 조금 낮았으나, 이후에는 현저히 낮아지는 것을 확인하였다. 또한, 혈당 누적 농도(area under curve, AUC) 역시 알릴이소시아네이트를 투여한 B군의 마우스가 A군에 비하여 낮은 것으로 확인되었다.As shown in Figure 4 and 5, the group B mice orally administered with allyl isocyanate slightly lower glucose levels up to 30 minutes compared to the group A mice, it was confirmed that after that it is significantly lower. In addition, the blood glucose concentration (area under curve, AUC) was also found to be lower than the group A mice to which allyl isocyanate was administered.
상기 결과를 통하여, 알릴이소시아네이트가 인슐린 민감도를 증가시킨다는 것을 알 수 있다.
The results show that allyl isocyanate increases insulin sensitivity.
시험예Test Example 4. 4. 당화혈색소Glycosylated hemoglobin (( HbA1cHbA1c ) 측정) Measure
4주간의 실험 종료 후 A 및 B군 마우스를 해부전에 12시간 절식시킨 후 공복상태에서 꼬리정맥으로부터 채혈하여 500mM EDTA가 소량 들어있는 튜브에 전혈 50 ㎕를 넣고 혼합한 후 in2it Analyzer(Bio-Rad)를 이용하여 당화혈색소를 측정하였으며, 그 평균값을 도 6에 나타내었다.After 4 weeks of experiment, group A and B mice were fasted for 12 hours prior to dissection, and blood was collected from the tail vein in an empty stomach, and 50 μl of whole blood was mixed in a tube containing a small amount of 500 mM EDTA, followed by in2it Analyzer (Bio-Rad) Using the glycated hemoglobin was measured, the average value is shown in FIG.
당화혈색소란 장기간 동안 혈중 포도당(혈당) 농도를 알기 위해 사용하는 혈색소의 한 형태이며, 높은 혈중 포도당 상태에 혈색소가 노출되면서 형성된다. 우리 몸의 혈액에는 120일 정도의 수명을 가진 적혈구가 존재하며, 적혈구 안에 있는 혈색소가 포도당과 결합하면서 당화혈색소를 형성한다. 당뇨환자에서 혈당이 잘 조절되지 않을 경우 당화혈색소의 수치가 증가하게 되며, 당화가 일어난 적혈구는 수명이 조금 짧아지기 때문에 당화혈색소 수치는 약 3개월간의 혈중 혈당 농도를 반영한다.Glycated hemoglobin is a form of hemoglobin that is used to determine blood glucose (glucose) levels for long periods of time and is formed by exposure of hemoglobin to high blood glucose. The blood of our body has a life span of about 120 days of red blood cells, and hemoglobin in the red blood cells combine with glucose to form glycated hemoglobin. If the blood sugar is poorly controlled in diabetic patients, the glycated hemoglobin level is increased, and the glycated hemoglobin has a shorter lifespan, so the glycated hemoglobin level reflects the blood glucose level for about 3 months.
도 6에 도시된 바와 같이, 알릴이소시아네이트를 경구 투여한 B군의 마우스는 A군의 마우스에 비하여 당화혈색소 수치가 낮은 것을 확인하였다.As shown in FIG. 6, the group B mice orally administered with allyl isocyanate were found to have lower glycated hemoglobin levels than the group A mice.
상기 결과를 통하여, 알릴이소시아네이트가 혈중 혈당을 감소시켜 혈당 조절능력이 있다는 것을 알 수 있다.
Through the above results, it can be seen that allyl isocyanate has a blood glucose control ability by reducing blood glucose.
시험예Test Example 5. 독성검사 5. Toxicity test
마우스의 췌장세포주인 NIT-1 세포를 48시간 동안 알릴이소시아네이트(AIC)와 알릴이소사이오시아네이트(AITC)로 처리한 후 세포 생존율을 측정하였으며, 이를 도 7에 나타내었다.Pancreatic cell lines of mice were treated with allyl isocyanate (AIC) and allyl isocyanate (AITC) for 48 hours, and then cell viability was measured.
도 7에 도시된 바와 같이, 알릴이소시아네이트(AIC)가 처리된 췌장세포는 생존율이 무처리 췌장세포(대조구)와 유사하였으나, 알릴이소사이오시아네이트(AITC)가 처리된 췌장세포는 생존율이 54.3%로 낮은 것을 확인하였다.
As shown in Figure 7, allyl isocyanate (AIC) -treated pancreatic cells were similar to untreated pancreatic cells (control), but allyl isocyanate (AITC) -treated pancreatic cells survived 54.3%. As low as confirmed.
하기에 본 발명의 알릴이소시아네이트를 함유하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, the formulation examples of the composition containing the allyl isocyanate of the present invention will be described, but the present invention is not intended to limit the present invention but merely to explain in detail.
제제예Formulation example 1. One. 산제의Sanje 제조 Produce
알릴이소시아네이트 500 mg
유당 100 mg
탈크 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.
The above components are mixed and filled in airtight bags to prepare powders.
제제예Formulation example 2. 정제의 제조 2. Preparation of tablets
알릴이소시아네이트 300 mgAllyl isocyanate 300 mg
옥수수전분 100 mg
유당 100 mg
스테아린산 마그네슘 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.
After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
제제예Formulation example 3. 캅셀제의 제조 3. Preparation of capsules
알릴이소시아네이트 200 mg
결정성 셀룰로오스 3 mg
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mgMagnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.
The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.
제제예Formulation example 4. 주사제의 제조 4. Preparation of injections
알릴이소시아네이트 600 mg
만니톨 180 mg180 mg mannitol
주사용 멸균 증류수 2974 mgSterile sterilized water for injection 2974 mg
Na2HPO4 ,12H2O 26 mgNa 2 HPO 4 , 12H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플 당 상기의 성분 함량으로 제조한다.
It is prepared by the above-mentioned component content per ampoule according to the usual injection preparation method.
제제예Formulation example 5. 5. 액제의Liquid 제조 Produce
알릴이소시아네이트 4 g4 g of allyl isocyanate
이성화당 10 g10 g of isomerized sugar
만니톨 5 g5 g of mannitol
정제수 적량Purified water
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100g으로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.
According to the conventional method of preparing a liquid solution, each component is added and dissolved in purified water, lemon flavor is added, the above ingredients are mixed, purified water is added, the whole is adjusted to 100 g by adding purified water, and then filled in a brown bottle and sterilized. To prepare a liquid solution.
제제예Formulation example 6. 과립제의 제조 6. Preparation of Granules
알릴이소시아네이트 1,000 mgAllyl Isocyanate 1,000 mg
비타민 혼합물 적량Vitamin mixture quantity
비타민 A 아세테이트 70 ㎍70 [mu] g of vitamin A acetate
비타민 E 1.0 mgVitamin E 1.0 mg
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mg0.15 mg of vitamin B2
비타민 B6 0.5 mgVitamin B6 0.5 mg
비타민 B12 0.2 ㎍0.2 [mu] g vitamin B12
비타민 C 10 mg
비오틴 10 ㎍Biotin 10 μg
니코틴산아미드 1.7 mgNicotinic acid amide 1.7 mg
엽산 50 ㎍50 ㎍ of folic acid
판토텐산 칼슘 0.5 mgCalcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture quantity
황산제1철 1.75 mg1.75 mg of ferrous sulfate
산화아연 0.82 mg0.82 mg of zinc oxide
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mgPotassium monophosphate 15 mg
제2인산칼슘 55 mgSecondary calcium phosphate 55 mg
구연산칼륨 90 mg
탄산칼슘 100 mg
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 과립제에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 과립제 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강기능식품 조성물 제조에 사용할 수 있다.
Although the composition ratio of the above-mentioned vitamin and mineral mixtures is a composition which is relatively suitable for granules in a preferred embodiment, the composition ratio may be arbitrarily modified, and the above components are mixed according to a conventional granulation method and then granulated. It can be prepared and used in the manufacture of health functional food composition according to a conventional method.
제제예Formulation example 7. 기능성 음료의 제조 7. Manufacture of functional beverages
알릴이소시아네이트 1,000 mgAllyl Isocyanate 1,000 mg
구연산 1,000 mgCitric acid 1,000 mg
올리고당 100 g100 g of oligosaccharide
매실농축액 2 gPlum concentrate 2 g
타우린 1 gTaurine 1 g
정제수를 가하여 전체 900 ㎖Purified water was added to a total of 900 ml
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85 ℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 기능성 음료 조성물 제조에 사용한다. The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The solution thus prepared was filtered and sterilized in a sterilized 2 L container, It is used in the production of the functional beverage composition of the invention.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.
Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.
Claims (8)
The health functional food according to claim 6, wherein the health functional food is selected from the group consisting of capsules, tablets, powders, granules, liquids, pills, flakes, pastes, syrups, gels, jellies and bars.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120112964A KR101355830B1 (en) | 2012-10-11 | 2012-10-11 | Pharmaceutical compositions and functional food for diabetes prevention comprising allyl isocyanate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120112964A KR101355830B1 (en) | 2012-10-11 | 2012-10-11 | Pharmaceutical compositions and functional food for diabetes prevention comprising allyl isocyanate |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101355830B1 true KR101355830B1 (en) | 2014-01-29 |
Family
ID=50146499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120112964A KR101355830B1 (en) | 2012-10-11 | 2012-10-11 | Pharmaceutical compositions and functional food for diabetes prevention comprising allyl isocyanate |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101355830B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101935848B1 (en) * | 2016-07-29 | 2019-01-09 | 농업회사법인 패시브바이오팜 주식회사 | Food composition for improving hyperglycemia using Brassica rapa |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100473484B1 (en) | 1995-09-15 | 2005-07-18 | 존스 홉킨스 스쿨 오브 메디슨 | Glucosinolates and isothiocyanates and sugar extraction methods from mustard plants or seeds, methods for producing cancer chemoprotective foods, pills or tablets, and related chemoprotective foods |
JP2007137794A (en) | 2005-11-16 | 2007-06-07 | Kinjirushi Kk | Wasabi leaf component composition and food and drug containing the same |
-
2012
- 2012-10-11 KR KR1020120112964A patent/KR101355830B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100473484B1 (en) | 1995-09-15 | 2005-07-18 | 존스 홉킨스 스쿨 오브 메디슨 | Glucosinolates and isothiocyanates and sugar extraction methods from mustard plants or seeds, methods for producing cancer chemoprotective foods, pills or tablets, and related chemoprotective foods |
JP2007137794A (en) | 2005-11-16 | 2007-06-07 | Kinjirushi Kk | Wasabi leaf component composition and food and drug containing the same |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101935848B1 (en) * | 2016-07-29 | 2019-01-09 | 농업회사법인 패시브바이오팜 주식회사 | Food composition for improving hyperglycemia using Brassica rapa |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100926944B1 (en) | Nutritional composition for blood sugar control | |
EP2011500B1 (en) | Fat accumulation inhibitor for the treatment of metabolic syndrome | |
US20090017167A1 (en) | Mixture and beverage made therefrom for protecting cellular hydration | |
WO2006119038A1 (en) | Compositions and methods for controlling glucose uptake | |
WO2012121140A1 (en) | Growth hormone secretion promoter | |
JP2013116918A (en) | Agent for ameliorating liver function | |
KR102483300B1 (en) | Composition for improving muscle atrophy comprising ginsenoside Rf, ginsenoside composition comprising gincenoside Rf, or mixture thereof as an effective component | |
KR101355830B1 (en) | Pharmaceutical compositions and functional food for diabetes prevention comprising allyl isocyanate | |
JP2010111646A (en) | Treating agent for ulcerative colitis | |
KR20200079206A (en) | Composition comprising an extract of Senna obtusifolia for preventing or treating diabetes mellitus | |
KR101883096B1 (en) | Pharmaceutical composition for preventing or treating acute lung injury or acute respiratory distress syndrome, comprising copper peptide | |
KR101266889B1 (en) | Functional food compositions having the recovery effect of blood composition and function | |
JP5394644B2 (en) | Muscle enhancer containing asperroside or its analog | |
RU2670612C2 (en) | Composition for preventing or treating obesity containing a-lipoic acid and n-acetylcysteine as active ingredients | |
KR101529279B1 (en) | Liver cytoprotective composition comprising an extract of brassica juncea coss. and compounds isolated therefrom | |
KR20180002157A (en) | A composition for removing hangover comprising an extract of Cinnamomum cassia Presl and cinnamomi petiole | |
KR101414040B1 (en) | Pharmaceutial composition comprising silkworm extract for regulation of blood glucose, herbal medicine and health food | |
JP5410152B2 (en) | Anemia prevention composition | |
KR101071511B1 (en) | Composition comprising the sugaring extract of Allium sativum L. for lowering blood glucose or preventing and treating diabetes mellitus | |
KR100583876B1 (en) | Healthy food containing kiwifruit extract for diebetes patient's diet | |
KR20140073432A (en) | Composition comprising an combined extract of dog rose and green tea seed as a main component for preventing and treating arthritis | |
KR102687132B1 (en) | A composition for the prevention or treatment of pain containin Plantago asiatica L extract | |
JP4831540B2 (en) | Oral hypnotics and hypnotic foods and drinks | |
KR101751393B1 (en) | Pharmaceutical composition for the prevention or treatment of muscle loss comprising linoleic acid or pharmaceutically acceptable salts thereof as an active ingredient | |
KR101785970B1 (en) | Pharmaceutical composition for the prevention or treatment of muscle loss comprising Oleic acid or pharmaceutically acceptable salts thereof as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20170102 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20180423 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20200102 Year of fee payment: 7 |
|
R401 | Registration of restoration |